Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infections

Microbes Infect. 2015 Feb;17(2):142-8. doi: 10.1016/j.micinf.2014.11.008. Epub 2014 Nov 29.

Abstract

The recent Middle East respiratory syndrome coronavirus (MERS-CoV) outbreak poses a serious threat to public health. Here, we summarize recent advances in identifying human neutralizing monoclonal antibodies (mAbs) against MERS-CoV, describe their mechanisms of action, and analyze their potential for treatment of MERS-CoV infections.

Keywords: Coronavirus; MERS-CoV; Receptor binding domain (RBD); mAbs.

Publication types

  • Research Support, N.I.H., Intramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Neutralizing / immunology
  • Antibodies, Neutralizing / therapeutic use*
  • Antibodies, Viral / immunology
  • Antibodies, Viral / therapeutic use
  • Communicable Disease Control
  • Coronavirus Infections / drug therapy*
  • Coronavirus Infections / prevention & control
  • Coronavirus Infections / virology
  • Humans
  • Middle East
  • Middle East Respiratory Syndrome Coronavirus / immunology*
  • Neutralization Tests

Substances

  • Antibodies, Monoclonal
  • Antibodies, Neutralizing
  • Antibodies, Viral